Skip to main content
Advertisement
Advertisement

GALT

GALT logo

Galectin Therapeutics Inc.

4.05
USD
Sponsored
-0.09
-2.17%
Sep 23, 15:59 UTC -4
Closed
exchange

After-Market

4.00

-0.05
-1.36%

GALT Earnings Reports

Positive Surprise Ratio

GALT beat 30 of 43 last estimates.

70%

Next Report

Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.05
Implied change from Q2 26 (Revenue/ EPS)
--
/
-64.29%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-61.54%

Galectin Therapeutics Inc. earnings per share and revenue

On Aug 14, 2026, GALT reported earnings of -0.14 USD per share (EPS) for Q2 26, missing the estimate of -0.09 USD, resulting in a -52.51% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.55% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an decrease of -64.29% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Galectin Therapeutics Inc. reported EPS of -$0.14, missing estimates by -52.51%, and revenue of $0.00, 0% as expectations.
The stock price moved down -2.55%, changed from $3.53 before the earnings release to $3.44 the day after.
The next earning report is scheduled for Nov 12, 2026.
Based on -- analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.05 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement